INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Open-market purchaseVerified data

Opaleye Management Inc. bought GRCE

10% Owner · Grace Therapeutics, Inc. · Common Stock, par value $0.0001 per share

Side
BUY
Value
$41K
Shares
21.4K
Price
$1.93
Executed
Oct 22, 2026
Disclosed
Oct 26, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Oct 22 executedOct 26, 2026 disclosed

GRCE · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
25/ 100 · ROUTINE
Methodology →
  • Transaction type+20 / 20

    Open-market purchase

  • Relative size+1 / 25

    $41K reported value · 0.7% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    3 prior trades recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · GRCE

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    28
    OM
    Opaleye Management Inc.10% Owner
    GRCEGrace Therapeutics, Inc.
    Open-market purchase
    		BUY$117K
    66.4K sh
    		Oct 26, 2026Oct 26, 2026
    traded Oct 26, 2026
    		+0dSEC FORM 4

    Evidence

    25
    OM
    Opaleye Management Inc.10% Owner
    GRCEGrace Therapeutics, Inc.
    Open-market purchase
    		BUY$8,001
    4,256 sh
    		Oct 19, 2026Oct 21, 2026
    traded Oct 19, 2026
    		+2dSEC FORM 4

    Evidence

    25
    OM
    Opaleye Management Inc.10% Owner
    GRCEGrace Therapeutics, Inc.
    Open-market purchase
    		BUY$11K
    5,318 sh
    		Sep 23, 2026Sep 23, 2026
    traded Sep 23, 2026
    		+0dSEC FORM 4

    Evidence

    29
    OM
    Opaleye Management Inc.10% Owner
    GRCEGrace Therapeutics, Inc.
    Open-market purchase
    		BUY$21K
    9,771 sh
    		Sep 21, 2026Sep 23, 2026
    traded Sep 21, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001493152-26-048591
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 22, 2026
    Published
    Oct 26, 2026
    Ingested by INSIDER
    Nov 5, 02:09 UTC
    Last re-read
    Nov 5, 02:09 UTC

    Extracted facts

    Filer
    Opaleye Management Inc.
    Role
    10% Owner
    Transaction
    Open-market purchaseAs filed: “P”
    Asset
    Grace Therapeutics, Inc.
    Ticker
    GRCE
    Shares
    21.4K
    Price per share
    $1.93
    Value
    $41,193
    Execution date (reported)
    Oct 22, 2026
    Owned after transaction
    2.97M shares
    Days from execution to publication
    4

    Calculation

    Value = shares × reported price per share

    • Shares: 21.4K
    • Price: $1.9258

    = $41,193

    What this establishes

    Opaleye Management Inc. filed this Form 4 reporting a open-market purchase of GRCE on Oct 22, 2026. It became public on Oct 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    10% Owner
    Opaleye Management Inc.cik:0001595855
    Issuer
    Grace Therapeutics, Inc.cik:0001444192

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.